The $7.2B Deal Hidden Inside the $47B Cannabis Crash
OR
a biopharma play disguised as a cannabis stock
Disclaimer: At the time of writing I personally own stocks in the company — bought at materially higher prices than today’s, and still bullish. (full disclaimer at end of page)
TL;DR — for busy founders & investors
Investment bankers poured $47 billion into cannabis and built 5x more capacity than the market wanted. The sector got vaporized.
In the middle of that wreckage, Jazz Pharmaceuticals paid $7.2 billion for GW Pharma. That single deal tells you the real story: some of those companies were never cannabis companies in the first place.
The dividing line is not the plant — it’s the formulation, and it has two levers:
(1) which cannabinoids you mix to hit which receptors (the entourage effect — multiple molecules, multiple targets), and
(2) how you deliver the dose so it actually reaches the bloodstream.
Basic formulations land 10–20% bioavailability; advanced delivery systems hit 70–80%.
Get either lever wrong and you don’t have a drug.
That’s where the IP and the moat live.US rescheduling matters far less for recreational and far more for medical:
it unlocks academic research, pharma partnerships, insurance coverage, and tax deductibility.
Canada is roughly 10 years ahead because it never had this handcuff.This is a biopharma thesis, not a cannabis thesis.
The label is the reason it’s cheap.
The science is the reason it shouldn’t be.
I thought the whole sector was a joke
For years, the cannabis sector was a punchline in my book. Bankers had pumped tens of billions of dollars into greenhouses, dispensaries, and licensing roll-ups. They built five times more growing capacity than anyone wanted to consume. Predictable result: a crash that destroyed an enormous amount of invested capital and an entire generation of retail confidence.
So I tuned out. For years.
Then one headline pulled me back in:
Jazz Pharmaceuticals buys GW Pharma for $7.2 billion in cash and stock.
In the middle of a sector that had been written off as a casino disguised as an industry, somebody wrote a $7.2B check. With cash on the table. That’s not a meme. That’s not a SPAC. That’s a strategic acquirer paying real money for something they value.
So I had to ask the obvious question: what did Jazz see that the rest of the market missed?
I had the chance to put that exact question to Aras Azadian, the CEO of Avicanna, a Toronto-listed company doing something different from the typical “cannabis stock.” Here’s how he framed the GW Pharma deal:
“I don’t think you can call GW Pharma a cannabis company. I think it’s a pharmaceutical company that created a cannabinoid-based pharmaceutical. It was the first one that obtained FDA approval. The company is doing north of a billion in sales.”
That’s the entire thesis in two sentences.
GW Pharma wasn’t priced like a cannabis company because it wasn’t one.
It was a pharma company that happened to use molecules from a plant that has terrible PR.
So the question becomes:
are there other companies in the wreckage that are also not really “cannabis companies”?
I think there are.
And I think Avicanna is one of them.
What the cannabis plant is actually for
Before we get to the company, we need to fix the language.
The phrase “medical cannabis” exists for a reason — and most investors instinctively flatten it into “weed with extra steps.”
That instinct is the entire reason the opportunity exists.
Look at the most expensive healthcare system in the world: the United States.
We have a default protocol for almost every problem — you go to a doctor, you get a pill.
The side effects of that pill show up later, so you go back to the doctor, and they give you a second pill.
Then a third.
Aras put it cleanly:
“Any problem that you have, you take a pill for it and don’t worry about the consequences. But there is consequence — liver, kidney, gut issues, all kinds of inflammatory diseases that come from chronic use of pharmaceuticals. And then for that, they tell you to take another pill.”
The default protocol isn’t a bug — it’s the loop.
Each new pill enters the patient as a fix and exits as the next problem to fix.
The whole system has a financial reason to keep running.
That isn’t an anti-pharma rant.
It’s a description of an incentive system that has been running for 150 years.
And it has produced enormous wins — antibiotics, vaccines, statins, oncology.
I’m not romanticizing the past.
But the model itself has limits.
Aras described those limits as:
“The medical pharmaceutical design of allopathic medicine over the last 150 years is sort of aged. We had this model of single molecule, single target, and we neglected other forms of medicine which we’ve used for thousands of years — plant-based medicine that happens to have a more synergistic effect of multiple molecules targeting multiple receptors.”
This is the part that changed my mind.
The endocannabinoid system:
A different kind of medicine
Our body has a built-in regulation network called the endocannabinoid system.
It’s the communication layer your body uses to balance
sleep,
pain,
inflammation,
mood, and
a long list of other functions.
Your body produces its own cannabinoids — that’s why the receptors are there in the first place.
CB1 receptors cluster in the brain and central nervous system;
CB2 receptors live mostly in the immune system, gut, and peripheral tissues.
The point of the map: this isn’t a single “target” — it’s a network the body already uses to keep itself in balance.
The mental model that helped me:
single molecule / single receptor is like setting the temperature on a hairdryer.
You target one tiny output.
Multi-target plant-based medicine is more like balancing the climate control across an entire house.
You’re acting on whole systems, not individual outputs.
That’s harder to measure.
That’s harder to write a clean clinical trial around.
And that’s exactly why it’s underexplored — and why it’s commercially open.
People call this the entourage effect — the idea that the active ingredients in the plant work better in combination than any one of them works alone.
And here is the unromantic version of what that means for an investor:
The science is harder.
The category is messier.
The label is uglier.
Most institutional capital won’t touch it (yet).
That’s the setup.
The real moat isn’t the plant — it’s the formulation
This is the single most important slide in the whole thesis.
There are actually two levers here — and getting either one wrong kills the drug:
The mix.
Which cannabinoids you combine, and in what ratio.
The plant has dozens of active compounds; the entourage effect means they work better together than alone.
Get the mix wrong and you’re acting on the wrong receptors — which means treating the wrong system, which means weak or unpredictable clinical effect. This is the part that’s hard to write a clean clinical trial around, and it’s most of the reason cannabinoid medicine has had such an inconsistent reputation.The delivery.
Even a perfect mix is useless if the dose doesn’t arrive in the bloodstream.
This is the part that’s easiest to quantify — so let’s start there.
If you give someone CBD in a basic coconut-oil formulation, only 10–20% of it actually reaches the bloodstream.
The rest is wasted.
That makes dosing wildly unreliable.
Which makes outcomes wildly unreliable, which makes physicians (rightly) skeptical, which keeps the category stuck.
Now compare that to a properly engineered drug-delivery system.
Aras’s number:
“In a more advanced drug delivery system or a more advanced formulation, you’re getting much higher absorption levels of 70, 80%.”
Read that again.
You go from 10–20% to 70–80%.
That isn’t a minor thingy.
That’s the difference between “interesting plant compound” and “real, dosable, prescribable medicine.”
impact of a proper delivery system
Same molecule, two different delivery systems.
The basic formulation loses the vast majority of the dose to first-pass metabolism in the liver.
An engineered carrier (lipid nanoparticle) gets 4–7× more of the active compound into the bloodstream — which is what makes it dosable enough to behave like a drug instead of a supplement.
Multiply the mix and the delivery together and you have a formulation that hits the right receptors and actually arrives.
This is where the IP lives.
This is where the moat lives.
And — critically — this is what a grower cannot copy overnight.
Aras’s line on this is the kind of thing that should be tattooed on every cannabis-sector PowerPoint:
“I don’t think you wake up one day and you change the DNA of your entire organization to go from having the best pre-rolls in the market to now having an entire medical affairs, patient support, and a standardized medicine platform.”
The grower companies are not one strategy pivot away from being biopharma companies.
They are an entire decade and an entire culture away.
That gap is the moat.
Why medical cannabis hasn’t broken out yet
If the science is real and the delivery problem is solvable, why hasn’t this category exploded?
Three real reasons, in order of impact:
Insurance coverage.
Most cannabinoid-based products aren’t reimbursed.
If your insurance covers the conventional pill for free, you’ll take the pill — even if a cannabinoid product would be objectively better for you.
Coverage is the unlock.Access and physician knowledge.
Dosing cannabinoids is non-trivial.
Many doctors haven’t been trained on it.
Patients don’t know where to start.
Friction kills adoption.Stigma.
Tell a colleague you’re taking cannabinoids for a medical condition and watch the eyebrow go up.
Aras nailed it:
“A lot of patients we hear are concerned about the optics.
What if their kids find out?
What if their parents find out?”
Stigma is solvable but slow.
All three of these are downstream of one structural thing:
the legal classification.
US rescheduling:
The lever almost nobody is pricing correctly
Cannabis is currently classified in the United States in the same schedule as heroin.
That is not a typo.
It is also not just a “weed-vibes” problem — it has money consequences:
Research is severely restricted.
Companies cannot deduct ordinary business expenses the way other businesses can (the so-called “280E tax handcuff”).
Institutional capital stays out because the classification creates explicit and implicit risk.
The Biden-era process to reschedule cannabis from Schedule I to Schedule III has been moving — slowly, painfully, but moving.
Most mainstream coverage frames this as a recreational story.
That is the wrong frame.
Aras’s read:
“For us, and I think for medical-oriented companies, the outcome is much more profound. This will allow the larger healthcare biotech institutions and pharmaceutical companies to enter and look at it more seriously. This will allow academic and clinical institutions in the United States to now conduct research. This is a major limiting factor for the United States until this rescheduling takes place. And that’s why Canada has been so far ahead.”
Translate that into investor language:
Pharma M&A pipeline opens up.
Big pharma can finally talk to cannabinoid biopharma companies.
Without their legal teams having a stroke.US academic research turns on.
Real andomized controlled trials (RCTs),
real publications,
real clinical guidelines.Insurance coverage becomes politically tractable.
Aras’s team is already doing insurance adjudication in Canada — there’s a working playbook to import.The 280E handcuff loosens for companies on the right side of the line.
And here’s the kicker:
Canada has had a roughly 10-year head start under a sane(r) regulatory regime.
That means a Canadian biopharma like Avicanna is sitting on real-world evidence, clinical data, regulatory experience, and product registrations that the US side is going to need the moment the door opens.
The pharma calls don’t go to the guys who just got into the game last quarter.
They go to the team that already has the dataset.
Roughly a decade of legal head-start on clinical research, real-world evidence, and insurance adjudication sits north of the border.
When US rescheduling lands, that gap doesn’t close overnight — it just becomes purchasable.
Avicanna (TSX: AVCN) — the setup
Avicanna is listed on the Toronto Stock Exchange under AVCN.
Reminder: I personally own shares, bought at higher prices than today’s, and I’m still long.
Avicanna owns every step from cultivation through patient access.
That’s not a vanity decision — standardized medicine requires controlling the input.
The grower model controls step 1 and outsources the rest.
The biopharma model needs all five, in sequence, under one roof.
The setup that made me move from “this is interesting” to “I’ll size a real position” (note: it’s still a small bet in my portfolio):
They grow their own plants.
That’s a quality and standardization decision, not a “we’re a cultivator” decision.
If you don’t control the input, you can’t build standardized medicine on top of it.They control both formulation levers.
That means the cannabinoid mix (which compounds, in which ratio, for which condition)
and
the delivery system (the proprietary tech that moves bioavailability from 10–20% into the 70–80% range).
Either lever alone doesn’t make a drug.
Both together do.They treat medical cannabis as a service, not a product.
Aras’s line: “I like to simplify medical cannabis and say it’s not a product, it’s a service.”
What that means in practice:
Pharmacist-driven dosing plans —> follow-up —> adjustments —> medical affairs —> patient support.
That’s the architecture of a healthcare company.
It is not the architecture of a dispensary.They’ve taken a product all the way through to a real regulatory registration.
Not “we have a plan to file” — actually registered as a pharmaceutical with a national regulator, in addition to being prescribed in Canada under medical cannabis.
That is rare in this sector and very hard to fake.
The same formulation shows up commercially under two names:
Trunerox — registered as a pharmaceutical in Colombia with INVIMA (the local regulator) for epilepsy sub-indications (Lennox-Gastaut and Dravet syndromes).
RHO Phyto MicroDrop 100 — sold in Canada under medical cannabis, prescribed by neurologists, used by epilepsy patients.
Same molecule, same formulation, two regulatory paths.
That’s how you bridge a category in transition — and that’s exactly the bridge a US pharma partner is going to want to lease.
(note: It’s way harder in the US to get sth classified in the due to different testing rules that are a big barrier if you’re targeting multiple receptors)
Why founder motivation actually matters here
This is a category where the science is messy, the regulation is fragile, and the financing cycles are brutal.
You don’t get through that on optionality.
You get through it on why.
I asked Aras for a story that grounds the work.
He described a child with severe early-onset seizures — multiple seizures a day, developmental issues, struggling to walk.
The father showed him video from two years later, after CBD oil: seizures stopped, behaving like a normal child.
Then last year the same girl, now five or six, walked on stage at their symposium with her mother and spoke as a patient.
You can fake a deck.
You can’t fake the way someone tells that story.
The other tell — what keeps Aras up at night:
“How do I further separate Avicanna from recreational cannabis companies has been my nine-year challenge. Sometimes it gets easier, sometimes it gets harder.”
Nine years of fighting the label is the kind of grind that creates moats.
It’s also the kind of grind that creates mispricing, because the label is exactly what makes generalist investors swipe past it.
How I’m thinking about the risks
I’d be lying if I said this was a clean, low-risk setup.
Here’s what I’m watching:
Capital structure and runway.
Micro-caps in transition categories tend to need to raise.
Dilution is a real risk;
read the filings.Rescheduling timing.
The medical thesis works without it, but the re-rating doesn’t happen until the regulatory door actually opens.
Political timing is not in your control.Insurance and reimbursement adoption outside Canada will be slow even after rescheduling.
This isn’t a quarter-by-quarter story.The “cannabis” label itself.
As long as Avicanna trades on the same screen as the growers, it will get screened out by a lot of capital.
That’s the bull case and the risk.Execution.
Drug delivery, regulatory work, and medical platforms are all hard, separately.
Doing all three at once is harder.
This is not a “back up the truck” stock for someone who can’t watch a micro-cap drawdown without flinching (my position currently is a huge big red … ).
It’s a thesis investment in a structural mispricing — sized accordingly.
The takeaway
The cannabis sector burned $47 billion building the wrong thing.
The market response was rational: write the whole category off.
But buried inside that wreckage is a smaller, harder, more interesting business — biopharma companies that use the cannabis plant as raw material for actual medicine.
GW Pharma proved those exist by selling for $7.2 billion in cash.
Avicanna is trying to be the next one to prove it.
The moat is the formulation — the cannabinoid mix plus the delivery system — not the plant.
The unlock is US rescheduling, not legalization.
The asymmetry is that the market still confuses these companies with growers — which is exactly why a position is possible at this price.
I own it.
I’m holding it.
I might buy more.
Watch this in Aras own words, and a different angle YouTube (click on it)
If you got value out of this kind of breakdown, the place to follow along is the newsletter — https://invest.andreasluksch.de/subscribe. I share my personal investment story, the conversations I get to have with company leaders, and the frameworks I’m building as I go.
See you in the next one.
— Andreas
Disclaimer
This publication is for informational & entertainment purposes only. It does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. The author is not a licensed financial advisor.
Investing in shares and financial instruments involves significant risks, including the potential loss of 100% of invested capital. Micro-cap and biopharma names are among the highest-risk segments of the market, and most early-stage drug-delivery and clinical programs do not succeed.
Forward-looking statements, forecasts, and targets are inherently uncertain and may not occur. Information is believed to be reliable but may not be complete, accurate, or independently verified. realations GmbH does not undertake any obligation to update this content in the future.
realations GmbH and its affiliates may hold, buy, or sell securities of companies mentioned, creating potential conflicts of interest. This publication is a business and may receive compensation for producing content; however, no company featured has paid realations GmbH directly for inclusion.
The views expressed are personal opinions. Guests may be speaking as part of their own marketing activities, and their statements do not represent realations GmbH.
Each reader remains solely responsible for their own investment decisions and should consult official filings (SEDAR+, SEC) and a licensed financial advisor before investing.
This publication is not a prospectus or offering document and does not create any liability on the part of realations GmbH. realations GmbH accepts no liability for direct or indirect losses arising from use of this information.
Not for distribution in the United States of America or Australia.
